Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ya i think the most we can hope for is eye and hair color out this year. Next year accreditation,Patent approval,FDA approval on Ovanome,maybe some more forensics features.Remember the twist interview 12 Million is expected in 2006 and 80 Million in 2007 what is going on in 2005 that would cause 12 Million in revenue in 2006.
I must add that even with eye and hair color out i dont think it will be enough to keep the pps up and by the time the forensics side of the comp. gets going with revenue it will be well into Mid 2005. In any case Dnap needs to start putting out products to get the volume needed to bring the pps up and keep it up.80 Million and more a day is what is needed,That will not happen without major news.
ustacud,One who asks a question is a fool for five minutes; one who does not ask a question remains a fool forever.It is a good thing to ask.I'm know expert but i think you already have part of the answer.Profits do push the pps up.And when you consider that Dnap has 11 Forensics products only one of them is on the market the money coming in is not bad. Thats 1/11 of the Forensics package thats out.Skin color
- Ancestry by Dna 2.5
- Eye color
- Hair color
- Height
- Weight
- Nose shape
- Distance between eyes
- Distance between cheekbones
- Whether earlobes attached
- Longitude and latitude of face
- Depth of cranium
When eye and hair come out profits will grow to a point where it will make a big difference. This shows that the comp. is for real,products ready for market. Then the demand will speak for it self.We need volume around 80 to 100 Million or more a day to really move the pps.For this to happen Dnap needs products ready to market and a product that is in High Demand.But if Tony does not do everything possible to reduce the error rate of the product once up, than NOTHING WILL STOP THE PPS FROM COMING DOWN. Take confort in knowing this,That when Tony comes out with eye and hair color there will be no one on earth who will be able to knock it down.It will be here to stay.$$$$$$$
All it does is confirm what Tony has been saying along.
Gcbr,there a little late Tony spoke about this years ago.That junk dna is really where to look.
You rat i got 16001
Albinism in Africa and human pigmentation genetics
Principal Investigator: Prof Michele Ramsay
Collaborators: Prof J Kromberg (Johannesburg - more recently Brisbane), Prof R Nicholls (Philadelphia), Dr R Sturm (Brisbane) and Dr W-H Li (Chicago), Dr S Kidson (Cape Town), Sr E Zwane (Johannesburg)
-- The main objective of this project is to improve our understanding of the different steps involved in the pigmentary pathway through the study of naturally occurring human pigment disorders. Oculocutaneous albinism (OCA) is a common genetic disorder in Africa with major health implications in terms of increased susceptibility to early onset skin cancer and the need for special education in schools for the partially sighted. In South African blacks the prevalence of OCA is 1 in 3900.
Over the past 10 years we have made significant progress towards understanding the molecular basis of oculocutaneous albinism 2 (OCA2 - MIM2032000). In 1992 the locus was mapped to chromosome 15q11.2-q12 and when the P was identified in the region it was shown that this was the locus involved in the South African OCA2 individuals. A common P gene mutation has been identified and is present in 77% of South African blacks (giving a frequency of 0.77). This mutation is a 2.7kb interstitial deletion which deleted exon 7, and which results in a downstream frameshift. In an effort to accurately predict the carrier frequency, 780 healthy unaffected individuals were studied and the carrier frequency of the 2.7kb deletion was shown to be 1 in 78 in South African black OCA2 individuals. If one corrects for a detection rate of 0.77, them the OCA2 carrier frequency is about 1 in 40. We screened the coding region of the P gene for mutations in the non-2.7kb deletion alleles of OCA2 patients who did not carry the deletion allele in either one or both of their P genes. We identified four mutations (A334V, 614delA, 683insT, 727insG) in a group of 39 unrelated black OCA2 patients with a total of 52 non-2.7kb deletion OCA2 genes. When taking all OCA2 cases into consideration, including those homozygous for the 2.7kb deletion mutation, these account for a further 1.7% of OCA2 mutations in southern African blacks, increasing the overall mutation detection rate to 78.7%. Three mutations (E678K, L688F, I370T) were identified in a group of 15 black patients with an initially unclassified type of OCA and another three mutations (IVS14-2(a*g), V350M, P743L) were identified in nine caucasoid OCA patients. Relatively few mutations, all with low frequency, were identified in the non-2.7kb deletion OCA genes suggesting that other mutations may lie either within intronic sequence, or within the promoter region of the gene.
Two other types of oculocutaneous albinism have been shown to be relatively common in southern African blacks, namely brown and rufous OCA. Brown OCA (BOCA - MIM 203290) has been shown to be allelic to OCA2 in South African blacks, with the majority of affected individuals being compound heterozygotes, with one 2.7kb deletion allele. Rufous OCA (ROCA - MIM 278400) has been shown to be caused by mutations in the tyrosinase-related protein 1 locus on chromosome 9p23. Two mutations, S166X and 368delA account for 0.95 of mutations in 19 unrelated affected individuals.
Current projects are aimed at identifying the promoter region of the P gene in order to search for OCA2 and BOCA mutations and at understanding the molecular basis of ephelides (pigmented patches) (see photograph) that occur in a large proportion of OCA2 affected individuals.
Preliminary studies on understanding the molecular basis of normal pigmentation differences in humans included exploring the role of the MC1R gene in normal pigment variation. The MC1R gene was studied in negroid and San populations and also in a group of individuals with red hair. The two African groups had fewer non-synonymous than synonymous substitutions. All red-haired individuals of European origin were either homozygotes or compound heterozygotes for MC1R mutations. Four novel mutations were detected in these individuals: S83P, Y152X, A171N and P256S.
stockboy,Ok thanks I wonder if we can add to the names after the meeting.
Easyman51, It is not the critic who counts, not the man who points out how the strong man stumbled, or where the doer of deeds could have done better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who strives valiantly, who errs and comes short again and again, who knows the great enthusiasms, the great devotions, and spends himself in a worthy cause, who at best knows achievement and who at the worst if he fails at least fails while daring greatly so that his place shall never be with those cold and timid souls who know neither victory nor defeat.
Easyman51,We do have a great investment here.It will both make us rich in many ways both in learning and in Money. Money for my self and my chrilden.The way i see it is theres to many checks and balances in place now for Tony to go wrong.To many interests at stake to many support systems for error.It seems with every passing week we find a new interest involved, No the powers to be at some point will take over and this thing will be bigger than Tony and will move like a raging Sea with a power of its own.The Dream becomes bigger than the dreamer.Much bigger !!!! $$$$$$$
Dnap employees:>>>>>>>>>>>>>>>>>>>>
1} Tony Nick Frudakis
2} Richard Gabriel
3} Monica Tamborini
4} Hector Gomez
5} Zack Gaskin
6} Karin A. McMurtrie
7} Matthew J. Thomas
00} K. Venkateswarlu Kondragunta - Toasted !! and gone
8} Suresh Chandra K.
9} Siva Ginjupallia
10} Sitaram Gunturia
11} Viswanatham K. Ponnuswamya
12} K.N. Ponnuswamya
13} Sivamani Natrajana
14} Ponnuswamy Kolathupalayam Nachimuthu
15} carrie cant forget carrie. LOL
Patience is a funny thing.Either way you go, she will have her way.You can wait with grace or with scorn.Patience will reveal who you are.And then people around you will know you.
Here is another Dr. that has done work with the human OCA2 gene {eye color}. http://www.ihg.med.umn.edu/people/king.html
"It is very gratifying that others have confirmed our work, and that the editors of a respected journal desire to review the research to which we are contributing," said Tony Frudakis, Chief Scientific Officer of DNAPrint genomics, Inc.
Rick Sturm, a pigmentation genetics expert from the University of Queensland, Brisbane Australia, co-authored the survey. Sturm's laboratory and the laboratory of Rick Martin (Queensland Institute of Medical Research, Brisbane Australia), from which the Zhu, et. al. paper originated, contacted DNAPrint last year and the three groups have been collaborating since.
From New release - "It is very gratifying that others have confirmed our work
Patience_pays,yes very encouraging.Here are just some of the names.1} Rosenberg N.Roger !!!; 2}Pritchard J.!!! ; 3}Weber J.; 4}Cann H.; 5}Kidd K.; 6}Zhivotovsky L.; 7}Feldman M.; 8}Underhill P.A.!!!; 9}Lell J.T.; 10}Sukernik R.I.; 11}Starikovskaya Y.B.; 12}Su B.; 13}Jin L.; 14}Schurr T.G.;15}Wallace D.C.; 15}Passarino G.; 16}Lin A.; 17}Shen P.; 18}Mirazon M. Lahr; 19}Foley R.; 20}Oefner P.; 21}Cavalli-Sforza L.; 22}Richard A. Sturm!!!; 23}David L. Duffy!!!;24}Neil F.; 25}Wei Chen; 26}James S.Palmer; 27}Grant W. Montgomery; 28}Michael R. James; 29}Nicholas K. Hayward; 30}Nicholas G. Martin; 31}Gu Zhu; 32}David M. Evans; 33}Sarah E. Medland; 34}Nathan A. Gillespie; 35}Kelly R.Ewen; 36}Mary Jewell; 37}Yew Wah Liew; 38}Jeffery M Trent!!!!; 39}Zhu G.; 40}Rick Martin; 41}Kapaeth Satyamoorthy; 42}Freidegund Meier!!!; 43}Brooke B. Gardiner; 44}Darren J. Smit; 45}Bhavesh Vaidya; 46}Meenhard Herlyn!!!; 47}Suzanne M Cutts!!!; 48}Andrew Masta; 49}Con Panousis; 50}Peter G. Parsons!!!; 51}Don R. Phillips; 52}Neil F. Box; 53}Timothy Joseph Yeatman; 54}Jack W. Pledger; 55}Richard Jove;56}Thomas Sellers; 57}Jose R. Fernandez;58}Mark Shriver; 58}Barbara A. Gower; 59}Michael I Goran 60}T. Mark Beasley; 61}Sonia Dios; 62}Rick Kittles; 63}Li Jin; 64}George Argyropoul; 65}Celina Jovel; 66}David B. Allison; 67}Esteban Parra J.; 68}Alice S. Ryan; 69}N. Patil; 70}C. Pfaff; 71}Paul M Mckeigue; 72}Clive L Hoggart; 73}Wake Forest; 74}Roland L. Weinsier; 75}Jeanine Albu; 76}Eric Boerwinkle; 77}Barbara Nicklas; 78}Patterson N.;79}Hattangadi N.; 80} Lane B.- All these Dr.'s are by no means the only ones.Along with these we have over half a dozen Universitys/Comp.'s working with Dnap in some way or another.University of Stanford; London School of Hygiene and Troical Medicine;University of south Florida;Queensland Universityschool of Life Science;Duke University; New York State University; Penn State University; University of Birmingham; Wake Forest University; the list goes on and on the Royal Canadian Mounted Police; New Scotland Yard and the London Metropolitan Police ;HOME LAND SECURITY and the List keeps getting Bigger and Bigger. There is much more that I have not listed here but you can start to understand the magnitude of this is stagering.
patience_pays, couldn't pick a better name.Over the last 2 weeks or so I must have looked up some 80 Top notch research scientists over the entire country.From New York {suny} to california and all points in between,As well as overseas and all of them I SAY ALL OF THEM ARE IN SOME WAY WORKING WITH DNAP. Now doesent that kinda make ya feel warm in side. LOL
I will not post anymore on Dr. Zhu G. because he's got more brains than i dont know what. I've look over about a dz. research papers by him and cant understand on line. And its just the way i like it.
Here's more by Dr. Zhu - You figure it out -
Off-axis electron holography and microstructure of Ba0.5Sr0.5TiO3 thin film grown on LaAlO3
Authors: H. F. Tian, H. C. Yu, X. H. Zhu, Y. G. Wang, D. N. Zheng, H. X.Yang, J. Q. Li
Comments: 14 pages, 4figures, submitted to APL
Subj-class: Materials Science; Strongly Correlated Electrons
Epitaxial Ba0.5Sr0.5TiO3 thin films grown on the (001) LaAlO3 substrates with the ferroelectric transition of about 250K have been investigated by TEM and off-axis electron holography. Cross-sectional TEM observations show that the 350nm-thick Ba0.5Sr0.5TiO3 film has a sharp interface with notable misfit dislocations. Off-axis electron holographic measurements reveal that, at low temperatures, the ferroelectric polarization results in systematic accumulations of negative charges on the interface and positive charges on the film surface, and, at room temperature, certain charges could only accumulate at the interfacial dislocations and other defective areas.
This Dr. Zhu G. is got more brains than cheese on the moon look at this and i dont even know what the heck he's talking about but it seems like he talking about the Longitude and latitude of face or maybe Distance between cheekbones,or how much mush is in the eye ball i dont know But i like having him on board -
**************************************************************
High Energy Physics - Phenomenology, abstract
hep-ph/0401246
From: Zhi-Hai Lin [view email]
Date: Fri, 30 Jan 2004 16:08:15 GMT (114kb)
Inclusive $J/\psi$ Productions at $e^+ e^-$ Colliders
Authors: K. Hagiwara, E. Kou, Z.-H. Lin, C.-F. Qiao, G.-H. Zhu
Comments: 25 pages with 8 figures
Report-no: KEK-TH-939, UCL-IPT-04-01
Inclusive $J/\psi$ productions in $e^+ e^-$ annihilation is studied in the framework of NRQCD. We first review the leading-order calculations of the cross sections for $e^+ e^- \to J/\psi c \bar{c}$ and $e^+ e^- \to J/\psi g g$ and find that their ratio is about 1:1.5 at $\sqrt{s}\simeq 10$\gev. This result is in conflict with the current measurements by the Belle Collaboration, which finds that the process $e^+e^- \to J/\psi c\bar{c}$ accounts for about 2/3 of all the prompt $J/\psi$'s. We show that the discrepancy in the total rate as well as in the $J/\psi$ momentum distributions can be resolved by considering a large renormalization $K$ factor ($K\simeq 4$) for the $J/\psi c \bar {c}$ cross section and by taking into account collinear suppression in the end-point energy region of $J/\psi g g$ production. Detailed studies of the model predictions in terms of the density matrix are performed and various momentum and angular distributions are presented as functions of the $K$ factors. These distributions can be used to determine the normalizations of each subprocess provided that the production and decay angular distributions do not alter much by higher order corrections.
By Ming. WGCU interview with Tony Frudakis from 19th July 2004
http://www.wgcu.org/listen/gulfcoast_live.asp
Some highlights:
They are not developing drugs yet but intend to.
The error rate of DNAWitness is 4-8% for any percentage measured.
They will use facial recognition software in conjunction with DNA Witness to construct digital sketches of suspects. Future traits to be covered by DNA Witness:
- Skin color
- Eye color
- Hair color
- Height
- Weight
- Nose shape
- Distance between eyes
- Distance between cheekbones
- Whether earlobes attached
- Longitude and latitude of face
- Depth of cranium
- Any unusual inherited traits e.g. skull shape
The interviewer referred to a paper that Tony has apparently written called "Pharmacogenomics: The Paradigm Shift". Not sure if, when, or in what journal this is to be published.
When asked about cardiac drug related classifier development, Tony mentioned that DNAP had concentrated on a number of types of drugs, and specifically mentioned ace inhibitors and statins.
When asked about ovarian cancer/chemotherapy confirmed that can predict taxol and carboplatin response (based on two genes) and said that they are in the later stages of validating ovanome and "discussing with various types of organizations mechanisms of getting this type of test used and accepted for compensation by insurance companies, etc."
Have a nice day all.
By worktoplay - Becoming more relevant?
http://64.233.167.104/search?q=cache:SMDsS3kr608J:www.csis.org/tnt/031104.pdf+Dr.+Tony+Frudakis&....
Biometrics and Counter-Terrorism
A Roundtable hosted by CSIS Transnational Threats Initiative
November 4, 2003
Biometrics and counter-terrorism was the key topic at a CSIS Biometrics Roundtable held on November 4, 2003. The roundtable hosted by the Transnational Threats Initiative, brought together speakers from corporate, academic, and the government communities to discuss the impact of biometrics on both terrorism and civil liberties.
Biometrics are an important security instrument as America and the world adapt to asymmetric warfare and the widespread use of fraudulent identification documents. The roundtable addressed civil liberty concerns that arise with the widespread use of biometrics technology, a sensitive political issue on which America has been largely silent. While there has been much discussion on biometric applications, very rarely have there been detailed efforts to address the constitutional implications of the technology.
In his keynote remarks, Jeff Jonas, founder and chief scientist of Systems Research and Development discussed the issue of identity in the age of asymmetric threat.
The first panel addressed future biometrics applications with highlights on homeland defense, intelligence surveillance, and forensic technology. Panel members included John Woodward, Director of the Biometrics Management Office at the Department of Defense, Dr. Tony Frudakis, Chief Scientific Officer and Founder of DNAPrint Genomics, Barry Hodge, President of AcSys Biometrics Corporation and Dr. Andrew Kirby, Senior Physical Scientists, Intelligence Technology and Innovation Center at the CIA.
The second panel addressed biometrics and the implications of civil liberties. Panel members included Dr. Margaret Johnson, Senior Lecturer from the Department of Computer Science at Stanford University, David Harris, President and Founder of Biometrics Council, Dr. Catherine Lotrionte, Adjunct Professor at Georgetown University and Dr. Anthony Arend, Professor of Government at Georgetown University.
The host of that event was the Transnational Threats Initiative. More information on that effort can be found here:
http://www.csis.org/tnt/
While organized crime is not a new phenomenon today, some governments find their authority besieged at home and their foreign policy interests imperiled abroad. Drug trafficking, links between drug traffickers and terrorists, smuggling of illegal aliens, massive financial and bank fraud, arms smuggling, potential involvement in the theft and sale of nuclear material, political intimidation, and corruption all constitute a poisonous brew—a mixture potentially as deadly as what we faced during the cold war.
R. James Woolsey
Former Director of Central Intelligence and
Transnational Threats Initiative Steering Committee Member
The Transnational Threats Initiative Steering Committee and Members List contains some interesting names. You'll recognize several of them as members and advisors to the Biological Threats Council, of which Tony Frudakis is an Advisory Member:
Steering Committee
Leadership
The project is chaired by William Webster, former Director of the CIA and FBI. CSIS Senior Adviser Arnaud de Borchgrave serves as Project Director, CSIS Senior Analyst Thomas Sanderson as the Deputy Director with CSIS Senior Adviser Robert Kupperman and CSIS Director of Studies Erik Peterson as Co-Directors.
Members
Hon. Duane Andrews: Former Assistant Secretary of Defense
Ms. Zoe Baird: President, John and Mary Markle Foundation
Hon. Robert C. Bonner: Former Administrator, DEA, currently Commissioner, U.S. Customs Service (on leave)
Hon. William Cohen: Former United States Senator, former Secretary of Defense, and currently Chairman and CEO, Cohen Group
Mr. Charles Connolly: Former CSO, Merrill Lynch
Hon. John Deutch: Former Director, CIA and currently Institute Professor, Department of Chemistry, MIT
Mr. Richard Fore: Chairman, Fore Property Company
Hon. Robert Gates: Former Director CIA and currently President, Texas A&M
Hon. Carol Hallett: Former Commissioner, U.S. Customs Service and current Vice Chairman, Aviation Safety Alliance Carmen Group and Senior Advisor, Air Transportation Association
Admiral James R. Hogg: U.S. Navy (Ret.) and currently Director, Strategic Studies Group, Naval War College
Hon. Fred Ikle: Former Under Secretary of Defense and currently Distinguished Scholar, CSIS
Dr. David Kay: Corporate Vice President-Homeland Security, SAIC
Hon. Stuart Knight: Former Director, Secret Service
Hon. Jon Kyl: United States Senator (R - AZ)
Dr. Walter Laquer: Distinguished Scholar, CSIS
Hon. Patrick Leahy: United States Senator (D - VT)
Mr. Ronald A. Marks: Director, Federal Business Development, Sytegra Federal
Hon. William McCollum: Former U.S. Representative (R - FL) and currently Partner, Baker & Hostetler, LLP
General Edward C. Meyer: Former Chief of Staff, U.S. Army and currently Chairman, Mitretek Systems Inc.
Hon. Sam Nunn: Former United States Senator
Mr. Oliver ("Buck") Revell: Former Associate Deputy Director, Federal Bureau of Investigation and currently President, Revell Group International, Inc.
Hon. Donald Rumsfeld: U.S. Secretary of Defense (on leave)
Hon. James R. Schlesinger: Former Secretary of Defense, former Secretary of Energy, former CIA Director, and currently Senior Advisor, Lehman Brothers, Inc.
Hon. William Sessions: Former Director, FBI and currently Partner, Holland & Knight, LLP
Admiral William D. Smith: U.S. Navy (Ret.) and Senior Fellow, Center for Naval Analyses
Lt. General Edward Soyster: Former Director, DIA and currently Vice President-International Operations, Military Professional Resources, Inc.
Hon. Richard Thornburgh: Former Attorney-General, former Governor of Pennsylvania and currently Counsel, Kirkpatrick & Lockhart LLP
Hon. William Webster: Senior Partner, Milbank, Tweed, Hadley & McCloy
Hon. Curt Weldon: U.S. Representative (R - PA)
Now THAT is quite a group...
Later,
W2P
ann441j, very nice post thankyou.
You are a blood cell zooming through arteries and veins.; You are an atom combining with others to create a new molecule.; You are an experimental drug attacking an infection.; While doctors and scientists might readily visualize such things, the rest of us often struggle to picture what's happening at the microscopic level.; But a Hartford-based software company, Exploria LLC, believes it has a way to make it easy -- one that could be worth millions to biotech and pharmaceutical companies, financial firms and others with complex stories to tell.; Exploria makes software tools that let companies put animations and video into their business presentations. Viewers get a vivid look at -- and understanding of -- everything from tiny chemical processes to complicated financial transactions.; The resulting ability to communicate complex information can be valuable indeed when the stakes are high, as they often are for business deals.; "We're a visual communications company. We empower people to get their message across," said Leo Herbette, the company's founder and chief executive.; A former professor of medicine at the University of Connecticut Health Center, Herbette first used video animations to help students in his lectures understand medical interactions.; "When you're trying to teach students intricate things like how the body works, you can verbalize some things, but it's so much easier to show them," Herbette said.; Soon, the word got out to other professors and research partners who began asking Herbette to make similar animations for them. That eventually led Herbette to found the company in 1993 as Exploria Productions.; For several years thereafter, Exploria was primarily a small production company creating scientifically accurate animations for clients like Esperion Therapeutics, a biopharmaceutical company based in Ann Arbor, Mich. Roger Newton, Esperion's chief executive, said Exploria's animation has proven invaluable in communicating the company's ideas and helping it raise $140 million in capital.; "Leo and his crew at Exploria have had a major impact on how well and how definitely we've been able to get our corporate message across," Newton said. "To show it visually by an animated approach has had a huge impact on helping people understand the science, which can bog people down --particularly investors."; But more recently, Exploria has also developed software able to display, transmit and update such presentations securely. Think of the Exploria's software as Microsoft Powerpoint on steroids, going far beyond the bullet-point slide shows now common at sales meetings, business conferences and college classrooms.; Exploria's software , which it calls its "Global Presentation System," also manages the transmission and updates of presentations.; Jay Ross, training director at Sankyo Pharma, a New Jersey-based drug company, said the ability to quickly update presentations and then distribute those updates to employees is an essential asset.; "We have sales representatives around the country," Ross said. "Our challenge is getting a standard, consistent training program out to everyone in the country with a demonstrated quality."; But it's not all science and biology. Plenty of other businesses also need to display complex information and update it often and securely.; For example, financial companies, such as Exploria client Marsh USA Inc., often need to push updated information to its representatives in the field. The company, a subsidiary of Marsh & McLennan, expects to use Exploria's technology to ensure its brokers get the latest marketing and financial information. The updates can simultaneously delete obsolete data, so brokers aren't working from outdated presentations.; Animated presentations created by Exploria for the BioBus, a mobile educational lab, also are being used to help middle school and high school students understand the science behind sickle cell anemia and lyme disease.; Exploria is privately held, and officials declined to reveal sales figures. But they said revenues are in the millions of dollars, grew by 50 percent last year and are on track to grow by even more this year. They said Exploria has been profitable since it was launched.; The company's client list already numbers about three dozen and includes large pharmaceutical companies such as Bristol Meyers Squibb and Park Davis, and financial services firms such as CIGNA and The Hartford.; Walter Borden, Exploria's vice president for sales and marketing, says the company's proprietary software for display and delivery will fuel its future growth. "We've grown substantially over the last couple of years and we're on a significant growth path," he said.; The company's software products are aimed at corporate customers. Pricing runs from a few thousand dollars for the simplest system to as much as $1 million for a full media library, management and delivery system.; Currently, Exploria employs 15 people in production and software development , but officials expect that number could double to 30 by the end of the year. Earlier this month, the company moved into 6,000 square feet of downtown office space at the corner of Trumbull and Asylum streets with options for more if it continues to grow.; Exploria's potential for rapid growth is quite real, according to Jeff Horn, executive director of Hartford's Beacon Technology Network, which helps young tech companies such as Exploria with fund- raising, partnerships, customers and sales.; "I clearly see them being over a $100 million company in the next four or five years," said Horn, a forecast that comes in at the high end of the company's own estimates.; PHOTOS: 3 (color); COURTESY OF Exploria LLC; Caption: MEDICALLY ACCURATE software animation is projected onto Leo Herbette, CEO of the Hartford software firm Exploria. Below, the firm's animation images depict nerve cells called neurons, left, and a protein in a cell membrane, right.
454 Corp - James Golden, a biotech executive who once planned a career in the space program, sometimes speaks in aerospace terms when discussing the life sciences.; "If you were comparing the future of genome science to that of the space program, the development of the genome sciences is where the V-2 rocket was in the mid-1940s. Maybe Sputnik, at the most," he said.; "The exciting work in genomics is just starting, and we feel our company will be making a large contribution."; Golden is manager of business development for 454 Corp., a young life sciences operation in Branford, Conn.; It is a spinoff of CuraGen Corp. of New Haven, and 454 typifies young dynamic companies that are forming to pursue advances in human-genome sequencing.; Since its establishment several years ago, 454 raised $40 million in its first round of financing from investors including CuraGen, Soros Fund Management LLC, Cooper Hill Partners LLC and private investors.; The company ramped up to 80 employees following the funding.; Golden was recently a panelist at a Springfield event dubbed "Business Opportunities in the Life Sciences."; He said that 454 is developing technologies for rapidly and comprehensively analyzing entire genomes.; The technology is expected to have applications in industrial engineering, agriculture, animal health, and human health care, including drug, discovery, development and disease diagnosis.; Company officials say they are introducing "revolutionary" technology that shortens the time and cost of current genome sequencing. (Some life sciences professionals predict that a person's genome someday will be analyzed cheaply and quickly. That would enable a person to determine illnesses to which she might be vulnerable, but right now the cost to analyze one individual's gene work is prohibitive.); The company is optimistic about the future, but Golden is not embracing the mythic "$1,000 genome."; Some futurists suggest that the cost will be $1,000 within the next several years. Others, including officials of U. S. Genomics in Woburn, say that a personal genome sequencing will be done in a matter of hours within three to four years.; Golden is not quite that optimistic.; "In the future I see the $100,000 genome," he said. "There has been a lot of hype around the business in recent years, and I don't think $1,000 is doable in the near future."; Golden is an example of an executive gravitating to life sciences after starting in another field.; He earned an undergraduate degree at Rhodes College in Memphis, Tenn., then earned an M. S. in computer science from the University of Tennessee Space Institute in Tullahoma, Tenn. Much of his graduate work was paid for by NASA.; He had planned a career with the space program. But as he saw the federal funding fade, he returned to school and received a Ph. D. in mechanical engineering from Vanderbilt University in Nashville, Tenn.; Golden's work at Vanderbilt included the design and optimization of DNA sequencing devices. He worked with several bioinformatics companies in the late '90s before coming to 454.; "It's a classic story of how I got interested in aerospace," Golden recalled. "I was about 6, staying with grandparents in Florida, and we went outside to see Apollo 11 lift off. I was determined to be involved in space when I grew up, which I did.; "But then the money ran out. I'm really enjoying life sciences, and think that genomics is an exciting field with a very large future."
--------------------------------------------------------------------------------
Ridgefield-based Markland Technologies said it intends to acquire BioDentity Systems Corp. in Ottawa, Canada, which specializes in integrated facial recognition solutions.; BioDentity is the first vendor to provide a comprehensive turn key face biometric security solution designed to enhance border control, aviation security and homeland security ; BioDentity's SecurIDent facial recognition technology and ID2PASS person and document inspection systems can be implemented as primary security and clearance systems or added to any existing facial recognition system to enhance performance and reliability, Markland Technologies said.; Joel Shaw, chief executive officer and founder of BioDentity, has agreed to join Markland Technologies. Shaw is a frequent advisor to border control and travel document-issuing authorities in North America and throughout the world. He has worked closely with the Canadian Passport Office, the U. S. Department of State and the US. Immigration and Naturalization Service.; The acquisition is a key component to Markland's strategy of providing comprehensive turn key solutions to the many security threats faced by the US. and other countries, Markland's executives anticipate the combined revenue base will lead to positive cash flow by the third quarter of this calendar year.; Markland's chairman, Robert Tarini, said the acquisition "will increase our asset base and lead to our goal of a major market listing in the very near term."; The letter of intent contemplates that Markland Technologie's will effect a "reverse stock split" prior to acquisition of BioDentity Systems. Giving effect to the anticipated reverse split, the number of Markland's outstanding shares of common stock would be reduced to about 5 million.
Human Authentication - Application Program Interface -
http://www.biometrics.org/REPORTS/HAAPI/
****************************************************************
Easyman51,I have only ONE problem with Dnap,and it really stress me to think of it. But its their WEB Site. Its a Freaken disaster.1}There is all kinds of Old info. on it.
2}Its not user friendly {there's 3 different web sites to go to and you cant get to either one From the other}3} The Forensics slot at their main web site is not updated and gives no access to the other one's.This cant be good for the Comp.It should be all One site with EASY ACCESS to each.Anything is better than what they have now.
1}http://www.dnaprint.com/
2}http://www.ancestrybydna.com/strorder.asp
3}http://dnawitness.net/
Easyman51, well said, I think Tony is doing it right. There's more to marking this product than most think.The programming is critical.It MUST BE USER FRIENDLEY and meet the parameters required.There are many variables to look at,including the stepping on of toes.That may invite {later on down the road} legal ramifications.There are many for one reason or another would like to see Dnap Fail. Also this product will be used exclusively in a court of law by both sides.The Error rate must be Very Low.If it gets knocked down in court than so do we on the stock exchange.
Ming. Tony said 4 to 8% error rate for each percentage given. That Sounds like all 11 are done, within 4 to 8% error rate.
Dizygotic Twinning Is Not Linked to Variation at the -Inhibin Locus on Human Chromosome 21
Grant W. Montgomery, David L. Duffy, Jeff Hall, Barbara R. Haddon, Masataka Kudo, Elizabeth A. Mcgee, James S. Palmer, Aaron J. Hsueh, Dorret I. Boomsma and Nicholas G. Martin
Genetic Epidemiology Laboratory, Queensland Institute of Medical Research and Joint Genetics Program, University of Queensland (G.W.M., D.L.D., B.R.H., J.S.P., N.G.M.), Brisbane, Queensland 4029, Australia; AxyS Pharmaceuticals, Inc. (J.H.), La Jolla, California 92037; Division of Reproductive Biology, Department of Gynecology and Obstetrics, Stanford University Medical Center (M.K., E.A.M., A.J.H.), Stanford, California 94305-5371; and Psychology Department, Free University (D.I.B.), 1081 HV Amsterdam, The Netherlands
Address all correspondence and requests for reprints to: Dr. Grant Montgomery, Queensland Institute of Medical Research, Post Office, Royal Brisbane Hospital, Queensland 4029, Australia. E-mail: grantM@qimr.edu.au.
Natural multiple pregnancy in women leading to dizygotic (DZ) twins is familial and varies across racial groups, suggesting a genetic predisposition. Mothers of DZ twins have a higher incidence of spontaneous multiple ovulation and elevated FSH concentrations. FSH release is controlled by feedback of inhibin peptides from the ovary, and immunization against inhibin -subunit results in an increased ovulation rate in animals. The inhibin -subunit is therefore a candidate gene for mutations that may increase the frequency of DZ twinning. Restriction digests of a PCR product from exon 1 with the enzyme SpeI detects a C/T polymorphism at bp 128 with two alleles of 447 and 323/124 bp. The polymorphism was typed in 1125 individuals from 326 pedigrees with 717 mothers of spontaneous DZ twins. The -inhibin locus mapped within 3 centimorgans of D2S164, and linkage with DZ twinning was excluded [decimal log odds ratio (LOD) score, -2.81 at = 0]. There was complete exclusion of linkage (LOD, less than -2) of a gene conferring relative risk 1.8 (s, >1.8) across the chromosome, except at the p-terminus region and a small peak (maximum LOD score, 0.6) in the region of D2S151-D2S326. Analysis using either recessive or dominant models excluded linkage with DZ twinning in this population (LOD score, less than -2.5) across chromosome 2. We conclude that dizygotic twinning is not linked to variation in the -inhibin locus. The results also suggest that mutations in other candidates on chromosome 2, including the receptor for FSH and the ßB-inhibin subunit (INHBB) cannot be major contributors to risk for DZ twinning.
Dr. James S. Palmer a little on Brown eyes - Interactive effects of MC1R and OCA2 on melanoma risk phenotypes
David L. Duffy1, Neil F. Box2, Wei Chen2, James S. Palmer1,2, Grant W. Montgomery1, Michael R. James1, Nicholas K. Hayward1, Nicholas G. Martin1 and Richard A. Sturm2,*
1Queensland Institute of Medical Research, Brisbane, Australia and 2Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
Received October 21, 2003; Accepted December 11, 2003
The relationships between MC1R gene variants and red hair, skin reflectance, degree of freckling and nevus count were investigated in 2331 adolescent twins, their sibs and parents in 645 twin families. Penetrance of each MC1R variant allele was consistent with an allelic model where effects were multiplicative for red hair but additive for skin reflectance. Of nine MC1R variant alleles assayed, four common alleles were strongly associated with red hair and fair skin (Asp84Glu, Arg151Cys, Arg160Trp and Asp294His), with a further three alleles having low penetrance (Val60Leu, Val92Met and Arg163Gln). These variants were separately combined for the purposes of this analysis and designated as strong ‘R’ (OR=63.3; 95% CI 31.9–139.6) and weak ‘r ’ (OR=5.1; 95% CI 2.5–11.3) red hair alleles. Red-haired individuals are predominantly seen in the R/R and R/r groups with 67.1 and 10.8%, respectively. To assess the interaction of the brown eye color gene OCA2 on the phenotypic effects of variant MC1R alleles we included eye color as a covariate, and also genotyped two OCA2 SNPs (Arg305Trp and Arg419Gln), which were confirmed as modifying eye color. MC1R genotype effects on constitutive skin color, freckling and mole count were modified by eye color, but not genotype for these two OCA2 SNPs. This is probably due to the association of these OCA2 SNPs with brown/green not blue eye color. Amongst individuals with a R/R genotype (but not R/r), those who also had brown eyes had a mole count twice that of those with blue eyes. This suggests that other OCA2 polymorphisms influence mole count and remain to be described.
* To whom correspondence should be addressed at: Institute for Molecular Bioscience, University of Queensland, Brisbane, Qld 4072, Australia. Tel: +61 733462038; Fax: +61 733462101; Email: r.sturm@imb.uq.edu.au
another Dr.who has done work on eye color and hair and more is Dr.James S. Palmer who has worked with Dnap.- Interactive effects of MC1R and OCA2 on melanoma risk phenotypes.
Duffy DL, Box NF, Chen W, Palmer JS, Montgomery GW, James MR, Hayward NK, Martin NG, Sturm RA.
Queensland Insititute of Medical Research, Brisbane, Australia.
The relationships between MC1R gene variants and red hair, skin reflectance, degree of freckling and nevus count were investigated in 2331 adolescent twins, their sibs and parents in 645 twin families. Penetrance of each MC1R variant allele was consistent with an allelic model where effects were multiplicative for red hair but additive for skin reflectance. Of nine MC1R variant alleles assayed, four common alleles were strongly associated with red hair and fair skin (Asp84Glu, Arg151Cys, Arg160Trp and Asp294His), with a further three alleles having low penetrance (Val60Leu, Val92Met and Arg163Gln). These variants were separately combined for the purposes of this analysis and designated as strong 'R' (OR=63.3; 95% CI 31.9-139.6) and weak 'r ' (OR=5.1; 95% CI 2.5-11.3) red hair alleles. Red-haired individuals are predominantly seen in the R/R and R/r groups with 67.1 and 10.8%, respectively. To assess the interaction of the brown eye color gene OCA2 on the phenotypic effects of variant MC1R alleles we included eye color as a covariate, and also genotyped two OCA2 SNPs (Arg305Trp and Arg419Gln), which were confirmed as modifying eye color. MC1R genotype effects on constitutive skin color, freckling and mole count were modified by eye color, but not genotype for these two OCA2 SNPs. This is probably due to the association of these OCA2 SNPs with brown/green not blue eye color. Amongst individuals with a R/R genotype (but not R/r), those who also had brown eyes had a mole count twice that of those with blue eyes. This suggests that other OCA2 polymorphisms influence mole count and remain to be described.
Easyman51,Thanks.That would mean BIG BUCKS, YA.
What vise among man !! you harbor !! You wont get to heaven that way,got to go another way !!!
GOOD BUY BAR CODES HELLO DNAP
All Read- WGCU interview with Tony Frudakis from 19th July 2004
http://www.wgcu.org/listen/gulfcoast_live.asp
Some highlights:
They are not developing drugs yet but intend to.
The error rate of DNAWitness is 4-8% for any percentage measured.
They will use facial recognition software in conjunction with DNA Witness to construct digital sketches of suspects. Future traits to be covered by DNA Witness:
- Skin color
- Eye color
- Hair color
- Height
- Weight
- Nose shape
- Distance between eyes
- Distance between cheekbones
- Whether earlobes attached
- Longitude and latitude of face
- Depth of cranium
- Any unusual inherited traits e.g. skull shape
The interviewer referred to a paper that Tony has apparently written called "Pharmacogenomics: The Paradigm Shift". Not sure if, when, or in what journal this is to be published.
When asked about cardiac drug related classifier development, Tony mentioned that DNAP had concentrated on a number of types of drugs, and specifically mentioned ace inhibitors and statins.
When asked about ovarian cancer/chemotherapy confirmed that can predict taxol and carboplatin response (based on two genes) and said that they are in the later stages of validating ovanome and "discussing with various types of organizations mechanisms of getting this type of test used and accepted for compensation by insurance companies, etc."
Have a nice day all.
By Ming. WGCU interview with Tony Frudakis from 19th July 2004
http://www.wgcu.org/listen/gulfcoast_live.asp
Some highlights:
They are not developing drugs yet but intend to.
The error rate of DNAWitness is 4-8% for any percentage measured.
They will use facial recognition software in conjunction with DNA Witness to construct digital sketches of suspects. Future traits to be covered by DNA Witness:
- Skin color
- Eye color
- Hair color
- Height
- Weight
- Nose shape
- Distance between eyes
- Distance between cheekbones
- Whether earlobes attached
- Longitude and latitude of face
- Depth of cranium
- Any unusual inherited traits e.g. skull shape
The interviewer referred to a paper that Tony has apparently written called "Pharmacogenomics: The Paradigm Shift". Not sure if, when, or in what journal this is to be published.
When asked about cardiac drug related classifier development, Tony mentioned that DNAP had concentrated on a number of types of drugs, and specifically mentioned ace inhibitors and statins.
When asked about ovarian cancer/chemotherapy confirmed that can predict taxol and carboplatin response (based on two genes) and said that they are in the later stages of validating ovanome and "discussing with various types of organizations mechanisms of getting this type of test used and accepted for compensation by insurance companies, etc."
Have a nice day all.
Thats $11,000 if someone wants the whole package done. $1,000 a Trait.